Tamsulosin
DrugOther names: Alna®
NCT Number: NCT02266537
The study was aimed to evaluate the pharmacological effect of different α-antagonists on phenylephrine induced pupil size in healthy male volunteers as pharmacological basis for Intraoperative floppy iris syndrome (IFIS)
Looking for future studies?
Notify Me21 year–55 year
Male
Interventional
Phase 1
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The following exclusion criteria are of special interest for this study:
Other names: Alna®
Other names: Uroxatral® uno
Other names: Cardular PP Uro®
Time frame: Baseline, 60 and 80 min after administration of phenylephrine (PE)
Time frame: Baseline, 60 and 80 min after administration of phenylephrine (PE)
Time frame: one week after cessation of drug
Time frame: Up to 29 days after first administration of α-antagonists
Time frame: Up to 8 days after last pupillometry
Time frame: Up to 8 days after last pupillometry
Time frame: Up to 8 days after last pupillometry
Time frame: 8 days after last pupillometry
Boehringer Ingelheim
Industry
A Parallel Group Study With Three Different α-antagonists and Placebo Once Daily Over Three Weeks to Assess Their Influence on the Extent of Weekly Phenylephrine-induced Mydriasis at Three Different Concentrations of Phenylephrine in Healthy Male Volunteers
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06068257
Breast Cancer, Breast Diseases
Orlando, Florida, United States
View Trial DetailsNCT06702423
Healthy
London, United Kingdom
View Trial DetailsNCT07223164
Healthy
Irvine, California, United States
View Trial DetailsNCT05595902
Healthy
Kadıköy, Istanbul, Turkey (Türkiye)
View Trial Details